Sign in →

Test Code PNRCH Drug Immunoassay Panel, Urine

Secondary ID

65061

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
AMPHU Amphetamines Confirmation, U Yes No
BARBU Barbiturates Confirmation, U Yes No
COKEU Cocaine and metabolite Conf, U Yes No
PCPU Phencyclidine Confirmation, U Yes No
THCU Carboxy-THC Confirmation, U Yes No

Testing Algorithm

Testing begins with screening tests for drugs of abuse including amphetamines, barbiturates, cocaine, phencyclidine, and tetrahydrocannabinol. Positives are confirmed and quantitated by definitive methods (gas chromatography-mass spectrometry for barbiturates, cocaine and metabolites, phencyclidine, and tetrahydrocannabinol metabolite) at an additional charge. Amphetamines that screen positive will be quantified with liquid chromatography-tandem mass spectrometry at an additional charge.

Method Name

Only orderable as part of profile. For more information see CSMP / Controlled Substance Monitoring Panel, Urine.

 

Screened by Immunoassay and Confirmed by Gas Chromatography-Mass Spectrometry (GC-MS) or Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Reporting Name

Drug Immunoassay Panel, U

Specimen Type

Urine


Advisory Information


The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the serum or urine drug screens (DSS / Drug Screen, Prescription/OTC, Serum or PDSU / Drug Screen, Prescription/OTC, Urine).



Specimen Required


Only orderable as part of profile. For more information see CSMP / Controlled Substance Monitoring Panel, Urine.

 

Container/Tube: Plastic, 60-mL urine bottle

Specimen Volume: 30 mL

Collection Instructions:

1. Collect a random urine specimen.

2. No preservative


Specimen Stability Information

Specimen Type Temperature Time Special Container
Urine Refrigerated (preferred) 14 days
  Frozen  14 days
  Ambient  72 hours

Reference Values

Only orderable as part of profile. For more information see CSMP / Controlled Substance Monitoring Panel, Urine.

 

Negative

Screening cutoff concentrations:

Amphetamines: 500 ng/mL

Barbiturates: 200 ng/mL

Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL

Phencyclidine: 25 ng/mL

Tetrahydrocannabinol carboxylic acid: 50 ng/mL

This report is intended for use in clinical monitoring or management of patients. It is not intended for use in employment-related testing.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved or is exempt by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

80307

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PNRCH Drug Immunoassay Panel, U In Process

 

Result ID Test Result Name Result LOINC Value
2573 Amphetamines 16369-1
2574 Barbiturates 70155-7
21652 Cocaine 19360-7
2578 Phencyclidine 18392-1
2664 Tetrahydrocannabinol 19416-7

Useful For

Detecting drug use involving amphetamines, barbiturates, cocaine, phencyclidine, and tetrahydrocannabinol

Specimen Minimum Volume

20 mL

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

This test uses the simple screening technique that involves immunologic testing for drugs by class. All positive immunoassay screening results are confirmed by gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS), and quantitated, before a positive result is reported.

 

This assay was designed to test for and confirm by GC/MS the following:

-Barbiturates

-Cocaine

-Phencyclidine

-Tetrahydrocannabinol

 

Confirmation by LC-MS/MS is completed for all amphetamines.

This test is intended to be used in a setting where the test results can be used to make a definitive diagnosis.

Interpretation

A positive result derived by this testing indicates that the patient has used 1 of the drugs detected by these techniques in the recent past. See individual tests (eg, AMPHU / Amphetamines Confirmation, Urine) for more information.

 

For information about drug testing, including estimated detection times, see Drugs of Abuse Testing at https://www.mayocliniclabs.com/test-info/drug-book/index.html

Clinical Reference

1. Physicians' Desk Reference: 60th edition. Montvale, NJ, Medical Economics Company, 2006

2. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 11th edition. Edited by LL Bruntman. New York, NY. McGraw-Hill Book Company, 2006

3. Langman LJ, Bechtel L, Holstege CP: Chapter 35. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company. 2011, pp 1109-1188

Day(s) and Time(s) Performed

Monday through Sunday

Analytic Time

Same day/1 day